Clinical management of HIV drug resistance

Viruses

Volumn 3, Issue 4, 2011, Pages 347-378

  Cortez, Karoll J ^a   Maldarelli, Frank ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Clinical management; Drug resistance testing; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; INTEGRASE INHIBITOR; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CLINICAL EVALUATION; ENZYME STRUCTURE; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; LABORATORY TEST; MUTATIONAL ANALYSIS; PATIENT COMPLIANCE; PHENOTYPE; REVIEW; STRUCTURE ANALYSIS; VIREMIA; VIRUS MUTATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79955654096     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v3040347     Document Type: Review

References (179)

1. Broder, S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antivir. Res. 2010, 85, 1-18.
2. Tsibris, A.M.; Hirsch, M.S. Antiretroviral therapy in the clinic. J. Virol. 2010, 84, 5458-5464.
3. Volberding, P.A.; Deeks, S.G. Antiretroviral therapy and management of HIV infection. Lancet 2010, 376, 49-62.
4. Paredes, R.; Clotet, B. Clinical management of HIV-1 resistance. Antivir. Res. 2010, 85, 245-265.
5. Hogg, R.S.; Bangsberg, D.R.; Lima, V.D.; Alexander, C.; Bonner, S.; Yip, B.; Wood, E.; Dong, W.W.; Montaner, J.S.; Harrigan, P.R. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med. 2006, 3, e356.
6. Little, S.J.; Frost, S.D.; Wong, J.K.; Smith, D.M.; Pond, S.L.; Ignacio, C.C.; Parkin, N.T.; Petropoulos, C.J.; Richman, D.D. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J. Virol. 2008, 82, 5510-5518.
7. Vo, T.T.; Ledergerber, B.; Keiser, O.; Hirschel, B.; Furrer, H.; Battegay, M.; Cavassini, M.; Bernasconi, E.; Vernazza, P.; Weber, R. Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J. Infect. Dis. 2008, 197, 1685-1694.
8. Huang, H.Y.; Daar, E.S.; Sax, P.E.; Young, B.; Cook, P.; Benson, P.; Cohen, C.; Scribner, A.; Hu, H. The prevalence of transmitted antiretroviral drug resistance in treatment-naive patients and factors influencing first-line treatment regimen selection. HIV Med. 2008, 9, 285-293.
9. Perelson, A.S.; Neumann, A.U.; Markowitz, M.; Leonard, J.M.; Ho, D.D. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271, 1582-1586.
10. Bonhoeffer, S.; Coffin, J.M.; Nowak, M.A. Human immunodeficiency virus drug therapy and virus load. J. Virol. 1997, 71, 3275-3278.
11. Coffin, J.M. HIV viral dynamics. AIDS 1996, 10, S75-S84.
12. Frost, S.D.; Nijhuis, M.; Schuurman, R.; Boucher, C.A.; Brown, A.J. Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: The relative roles of drift and selection. J. Virol. 2000, 74, 6262-6268.
13. Johnson, J.A.; Li, J.F.; Morris, L.; Martinson, N.; Gray, G.; McIntyre, J.; Heneine, W. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J. Infect. Dis. 2005, 192, 16-23.
14. Palmer, S.; Boltz, V.; Maldarelli, F.; Kearney, M.; Halvas, E.K.; Rock, D.; Falloon, J.; Davey, R.T. Jr.; Dewar, R.L.; Metcalf, J.A.; Mellors, J.W.; Coffin, J.M. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS 2006, 20, 701-710.
15. Hu, W.S.; Rhodes, T.; Dang, Q.; Pathak, V. Retroviral recombination: Review of genetic analyses. Front. Biosci. 2003, 8, d143-d155.
16. Barry, M.; Gibbons, S.; Back, D.; Mulcahy, F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin. Pharmacokinet. 1997, 32, 194-209.
17. Preston, S.L.; Piliero, P.J.; Drusano, G.L. Pharmacodynamics and clinical use of anti-HIV drugs. Infect. Dis. Clin. North Am. 2003, 17, 651-674.
18. Demeter, L.M.; Jiang, H.; Mukherjee, A.L.; Morse, G.D.; DiFrancesco, R.; DiCenzo, R.; Dykes, C.; Sista, P.; Bacheler, L.; Klingman, K.; Rinehart, A.; Albrecht, M. A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients. AIDS 2009, 23, 357-368.
19. Kredo, T.; Van der Walt, J.S.; Siegfried, N.; Cohen, K. Therapeutic drug monitoring of antiretrovirals for people with HIV. Cochrane Database Syst. Rev. 2009, CD007268.
20. Simoni, J.M.; Amico, K.R.; Pearson, C.R.; Malow, R. Strategies for promoting adherence to antiretroviral therapy: a review of the literature. Curr. Infect. Dis. Rep. 2008, 10, 515-521.
21. Simoni, J.M.; Amico, K.R.; Smith, L.; Nelson, K. Antiretroviral adherence interventions: Translating research findings to the real world clinic. Curr. HIV/AIDS Rep. 2010, 7, 44-51.
22. Hart, J.E.; Jeon, C.Y.; Ivers, L.C.; Behforouz, H.L.; Caldas, A.; Drobac, P.C.; Shin, S.S. Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review. J. Acquir. Immune Defic. Syndr. 2010, 54, 167-179.
23. de Bruin, M.; Viechtbauer, W.; Schaalma, H.P.; Kok, G.; Abraham, C.; Hospers, H.J. Standard care impact on effects of highly active antiretroviral therapy adherence interventions: A meta-analysis of randomized controlled trials. Arch. Intern. Med. 2010, 170, 240-250.
24. Rosenblum, M.; Deeks, S.G.; van der Laan, M.; Bangsberg, D.R. The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PLoS ONE 2009, 4, e7196.
25. Bello, G.; Casado, C.; Sandonis, V.; Alvaro-Cifuentes, T.; Dos Santos, C.A.; Garcia, S.; Rodriguez, C.; Del Romero, J.; Pilotto, J.H.; Grinsztejn, B.; Veloso, V.G.; Morgado, M.G.; Lopez-Galindez, C. Plasma viral load threshold for sustaining intrahost HIV type 1 evolution. AIDS Res. Hum. Retroviruses 2007, 23, 1242-1250.
26. Persaud, D.; Pierson, T.; Ruff, C.; Finzi, D.; Chadwick, K.R.; Margolick, J.B.; Ruff, A.; Hutton, N.; Ray, S.; Siliciano, R.F. A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. J. Clin. Invest. 2000, 105, 995-1003.
27. Martinez-Picado, J.; DePasquale, M.P.; Kartsonis, N.; Hanna, G.J.; Wong, J.; Finzi, D.; Rosenberg, E.; Gunthard, H.F.; Sutton, L.; Savara, A.; Petropoulos, C.J.; Hellmann, N.; Walker, B.D.; Richman, D.D.; Siliciano, R.; D'Aquila, R.T. Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 10948-10953.
28. Shen, L.; Siliciano, R.F. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J. Allergy Clin. Immunol. 2008, 122, 22-28.
29. Maldarelli, F. Targeting viral reservoirs: Ability of antiretroviral therapy to stop viral replication. Curr. Opin. HIV AIDS 2011, 6, 49-56.
30. Buzon, M.J.; Massanella, M.; Llibre, J.M.; Esteve, A.; Dahl, V.; Puertas, M.C.; Gatell, J.M.; Domingo, P.; Paredes, R.; Sharkey, M.; Palmer, S.; Stevenson, M.; Clotet, B.; Blanco, J.; Martinez-Picado, J. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat. Med. 2010, 16, 460-465.
31. Lakhman, S.S.; Ma, Q.; Morse, G.D. Pharmacogenomics of CYP3A: Considerations for HIV treatment. Pharmacogenomics 2009, 10, 1323-1339.
32. Aihara, M. Pharmacogenetics of cutaneous adverse drug reactions. J. Dermatol. 2011, 38, 246-254.
33. Grant, R.M.; Kuritzkes, D.R.; Johnson, V.A.; Mellors, J.W.; Sullivan, J.L.; Swanstrom, R.; D'Aquila, R.T.; Van Gorder, M.; Holodniy, M.; Lloyd Jr, R.M. Jr.; Reid, C.; Morgan, G.F.; Winslow, D.L. Accuracy of the TRUGENE HIV-1 genotyping kit. J. Clin. Microbiol. 2003, 41, 1586-1593.
34. Pandit, A.; Mackay, W.G.; Steel, C.; van Loon, A.M.; Schuurman, R. HIV-1 drug resistance genotyping quality assessment: results of the ENVA7 Genotyping Proficiency Programme. J. Clin. Virol. 2008, 43, 401-406.
35. Thompson, M.A.; Aberg, J.A.; Cahn, P.; Montaner, J.S.; Rizzardini, G.; Telenti, A.; Gatell, J.M.; Gunthard, H.F.; Hammer, S.M.; Hirsch, M.S.; Jacobsen, D.M.; Reiss, P.; Richman, D.D.; Volberding, P.A.; Yeni, P.; Schooley, R.T. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010, 304, 321-333.
36. Labayru, C.; Eiros, J.M.; Hernandez, B.; de Lejarazu, R.O.; Torres, A.R. RNA extraction prior to HIV-1 resistance detection using Line Probe Assay (LiPA): comparison of three methods. J. Clin. Virol. 2005, 32, 265-271.
37. Lalonde, M.S.; Troyer, R.M.; Syed, A.R.; Bulime, S.; Demers, K.; Bajunirwe, F.; Arts, E.J. Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies. J. Clin. Microbiol. 2007, 45, 2604-2615.
38. Re, M.C.; Monari, P.; Bon, I.; Gibellini, D.; Vitone, F.; Borderi, M.; La Placa, M. Analysis of HIV-1 drug resistant mutations by line probe assay and direct sequencing in a cohort of therapy naive HIV-1 infected Italian patients. BMC Microbiol. 2001, 1, 30.
39. Adachi, A.; Gendelman, H.E.; Koenig, S.; Folks, T.; Willey, R.; Rabson, A.; Martin, M.A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 1986, 59, 284-291.
40. Fisher, A.G.; Collalti, E.; Ratner, L.; Gallo, R.C.; Wong-Staal, F. A molecular clone of HTLV-III with biological activity. Nature 1985, 316, 262-265.
41. Brun-Vezinet, F.; Costagliola, D.; Khaled, M.A.; Calvez, V.; Clavel, F.; Clotet, B.; Haubrich, R.; Kempf, D.; King, M.; Kuritzkes, D.; Lanier, R.; Miller, M.; Miller, V.; Phillips, A.; Pillay, D.; Schapiro, J.; Scott, J.; Shafer, R.; Zazzi, M.; Zolopa, A.; DeGruttola, V. Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir. Ther. 2004, 9, 465-478.
42. Vercauteren, J.; Vandamme, A.M. Algorithms for the interpretation of HIV-1 genotypic drug resistance information. Antivir. Res. 2006, 71, 335-342.
43. HIV Drug Resistance Website. Available online: http://hivdb.stanford.edu (accessed on 21 February 2011).
44. Garcia-Lerma, J.G.; Nidtha, S.; Blumoff, K.; Weinstock, H.; Heneine, W. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 13907-13912.
45. Stephan, C.; Dauer, B.; Bickel, M.; Haberl, A.; Locher, L.; Muller, A.; Klauke, S.; Berger, A.; Doerr, H.W.; Sturmer, M.; Staszewski, S. Intensification of a failing regimen with zidovudine may cause sustained virologic suppression in the presence of resensitising mutations including K65R. J. Infect. 2010, 61, 346-350.
46. Shi, C.; Mellors, J.W. A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 1997, 41, 2781-2785.
47. Hertogs, K.; de Bethune, M.P.; Miller, V.; Ivens, T.; Schel, P.; Van Cauwenberge, A.; Van Den Eynde, C.; Van Gerwen, V.; Azijn, H.; et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 1998, 42, 269-276.
48. Petropoulos, C.J.; Parkin, N.T.; Limoli, K.L.; Lie, Y.S.; Wrin, T.; Huang, W.; Tian, H.; Smith, D.; Winslow, G.A.; Capon, D.J.; Whitcomb, J.M. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2000, 44, 920-928.
49. Kellam, P.; Larder, B.A. Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 1994, 38, 23-30.
50. Debiaggi, M.; Bruno, R.; Sacchi, P.; Achilli, G.; Romero, E.; Filice, G. Distinct mutational drug resistance profiles of HIV-1 RNA in plasma and culture isolates of patients receiving antiretroviral therapy. Intervirology 2002, 45, 52-55.
51. Qari, S.H.; Respess, R.; Weinstock, H.; Beltrami, E.M.; Hertogs, K.; Larder, B.A.; Petropoulos, C.J.; Hellmann, N.; Heneine, W. Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1. J. Clin. Microbiol. 2002, 40, 31-35.
52. Robinson, L.H.; Myers, R.E.; Snowden, B.W.; Tisdale, M.; Blair, E.D. HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays. AIDS Res. Hum. Retroviruses 2000, 16, 1149-1156.
53. Prabu-Jeyabalan, M.; Nalivaika, E.A.; King, N.M.; Schiffer, C.A. Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. J. Virol. 2004, 78, 12446-12454.
54. Kolli, M.; Stawiski, E.; Chappey, C.; Schiffer, C.A. Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance. J. Virol. 2009, 83, 11027-11042.
55. Swanstrom, R.; Bosch, R.J.; Katzenstein, D.; Cheng, H.; Jiang, H.; Hellmann, N.; Haubrich, R.; Fiscus, S.A.; Fletcher, C.V.; Acosta, E.P.; Gulick, R.M. Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects. J. Infect. Dis. 2004, 190, 886-893.
56. Harrigan, P.R.; Montaner, J.S.; Wegner, S.A.; Verbiest, W.; Miller, V.; Wood, R.; Larder, B.A. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 2001, 15, 1671-1677.
57. Winters, B.; Montaner, J.; Harrigan, P.R.; Gazzard, B.; Pozniak, A.; Miller, M.D.; Emery, S.; van Leth, F.; Robinson, P.; Baxter, J.D.; et al. Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data. J. Acquir. Immune Defic. Syndr. 2008, 48, 26-34.
58. Mazzotta, F.; Lo Caputo, S.; Torti, C.; Tinelli, C.; Pierotti, P.; Castelli, F.; Lazzarin, A.; Angarano, G.; Maserati, R.; Gianotti, N.; et al. Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. J. Acquir. Immune Defic. Syndr. 2003, 32, 268-280.
59. Saracino, A.; Monno, L.; Locaputo, S.; Torti, C.; Scudeller, L.; Ladisa, N.; Antinori, A.; Sighinolfi, L.; Chirianni, A.; Mazzotta, F.; Carosi, G.; Angarano, G. Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open-label, randomized, multicenter study (PhenGen). J. Acquir. Immune Defic. Syndr. 2004, 37, 1587-1598.
60. Torti, C.; Quiros-Roldan, E.; Regazzi, M.; De Luca, A.; Mazzotta, F.; Antinori, A.; Ladisa, N.; Micheli, V.; Orani, A.; Patroni, A.; Villani, P.; Lo Caputo, S.; Moretti, F.; Di Giambenedetto, S.; Castelnuovo, F.; Maggi, P.; Tinelli, C.; Carosi, G. A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study. Clin. Infect. Dis. 2005, 40, 1828-1836.
61. Beerenwinkel, N.; Daumer, M.; Oette, M.; Korn, K.; Hoffmann, D.; Kaiser, R.; Lengauer, T.; Selbig, J.; Walter, H. Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic. Acids Res. 2003, 31, 3850-3855.
62. Geno2pheno 3.2. Available online: www.geno2pheno.org (accessed on 21 February, 2011).
63. HIV French Resistance Website. Available online: http://www.hivfrenchresistance.org (accessed on 21 February, 2011).
64. REGA. Available online: http://regaweb.med.kuleuven.be/software/rega_algorithm/ (accessed on 21 February 2011).
65. Altmann, A.; Sing, T.; Vermeiren, H.; Winters, B.; Van Craenenbroeck, E.; Van der Borght, K.; Rhee, S.Y.; Shafer, R.W.; Schulter, E.; Kaiser, R.; et al. Advantages of predicted phenotypes and statistical learning models in inferring virological response to antiretroviral therapy from HIV genotype. Antivir. Ther. 2009, 14, 273-283.
66. Liu, T.F.; Shafer, R.W. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin. Infect. Dis. 2006, 42, 1608-1618.
67. IASUSA. Available online: http://www.iasusa.org/resistance_mutations/index.html (accessed on 21 February, 2011).
68. Maldarelli, F. HIV drug resistance. In Handbook of Pediatric HIV Care; Zeichner, S., Read, J., Eds.; Cambridge University Press: Cambridge, UK, 2006.
69. Hales, G.; Birch, C.; Crowe, S.; Workman, C.; Hoy, J.F.; Law, M.G.; Kelleher, A.D.; Lincoln, D.; Emery, S. A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: the CREST study. PLoS Clin. Trials 2006, 1, e18.
70. Hsu, A.; Isaacson, J.; Brun, S.; Bernstein, B.; Lam, W.; Bertz, R.; Foit, C.; Rynkiewicz, K.; Richards, B.; King, M.; Rode, R.; Kempf, D.J.; Granneman, G.R.; Sun, E. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 2003, 47, 350-359.
71. Marcelin, A.G.; Cohen-Codar, I.; King, M.S.; Colson, P.; Guillevic, E.; Descamps, D.; Lamotte, C.; Schneider, V.; Ritter, J.; Segondy, M.; et al. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 2005, 49, 1720-1726.
72. Shen, L.; Peterson, S.; Sedaghat, A.R.; McMahon, M.A.; Callender, M.; Zhang, H.; Zhou, Y.; Pitt, E.; Anderson, K.S.; Acosta, E.P.; Siliciano, R.F. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat. Med. 2008, 14, 762-766.
73. Henrich, T.J.; Ribaudo, H.J.; Kuritzkes, D.R. Instantaneous inhibitory potential is similar to inhibitory quotient at predicting HIV-1 response to antiretroviral therapy. Clin. Infect. Dis. 2010, 51, 93-98.
74. Durant, J.; Clevenbergh, P.; Halfon, P.; Delgiudice, P.; Porsin, S.; Simonet, P.; Montagne, N.; Boucher, C.A.; Schapiro, J.M.; Dellamonica, P. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial. Lancet 1999, 353, 2195-2199.
75. Cohen, C.J.; Hunt, S.; Sension, M.; Farthing, C.; Conant, M.; Jacobson, S.; Nadler, J.; Verbiest, W.; Hertogs, K.; Ames, M.; Rinehart, A.R.; Graham, N.M. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002, 16, 579-588.
76. Cingolani, A.; Antinori, A.; Rizzo, M.G.; Murri, R.; Ammassari, A.; Baldini, F.; Di Giambenedetto, S.; Cauda, R.; De Luca, A. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: A randomized study (ARGENTA). AIDS 2002, 16, 369-379.
77. Meynard, J.L.; Vray, M.; Morand-Joubert, L.; Race, E.; Descamps, D.; Peytavin, G.; Matheron, S.; Lamotte, C.; Guiramand, S.; Costagliola, D.; Brun-Vezinet, F.; Clavel, F.; Girard, P.M. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002, 16, 727-736.
78. Tural, C.; Ruiz, L.; Holtzer, C.; Schapiro, J.; Viciana, P.; Gonzalez, J.; Domingo, P.; Boucher, C.; Rey-Joly, C.; Clotet, B. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002, 16, 209-218.
79. Durant, J.; Clevenbergh, P.; Garraffo, R.; Halfon, P.; Icard, S.; Del Giudice, P.; Montagne, N.; Schapiro, J.M.; Dellamonica, P. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt Study. AIDS 2000, 14, 1333-1339.
80. Baxter, J.D.; Mayers, D.L.; Wentworth, D.N.; Neaton, J.D.; Hoover, M.L.; Winters, M.A.; Mannheimer, S.B.; Thompson, M.A.; Abrams, D.I.; Brizz, B.J.; Ioannidis, J.P.; Merigan, T.C. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000, 14, F83-F93.
81. Zolopa, A.R.; Lazzeroni, L.C.; Rinehart, A.; Vezinet, F.B.; Clavel, F.; Collier, A.; Conway, B.; Gulick, R.M.; Holodniy, M.; Perno, C.F.; Shafer, R.W.; Richman, D.D.; Wainberg, M.A.; Kuritzkes, D.R. Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study). Clin. Infect. Dis. 2005, 41, 92-99.
82. Haubrich, R.H.; Kemper, C.A.; Hellmann, N.S.; Keiser, P.H.; Witt, M.D.; Tilles, J.G.; Forthal, D.N.; Leedom, J.; Leibowitz, M.; McCutchan, J.A.; Richman, D.D. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS 2005, 19, 295-302.
83. Panidou, E.T.; Trikalinos, T.A.; Ioannidis, J.P. Limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta-analysis. AIDS 2004, 18, 2153-2161.
84. Palella, F.J. Jr.; Armon, C.; Buchacz, K.; Cole, S.R.; Chmiel, J.S.; Novak, R.M.; Wood, K.; Moorman, A.C.; Brooks, J.T. The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: A cohort study. Ann. Intern. Med. 2009, 151, 73-84.
85. Panel on Antiretroviral Guidelines for Adults and Adolescents. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 1 December 2009; pp. 1-161.
86. Gazzard, B.G.; Anderson, J.; Babiker, A.; Boffito, M.; Brook, G.; Brough, G.; Churchill, D.; Cromarty, B.; Das, S.; Fisher, M.; et al. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008, 9, 563-608.
87. Sarafianos, S.G.; Marchand, B.; Das, K.; Himmel, D.M.; Parniak, M.A.; Hughes, S.H.; Arnold, E. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J. Mol. Biol. 2009, 385, 693-713.
88. Sarafianos, S.G.; Das, K.; Clark, A.D. Jr.; Ding, J.; Boyer, P.L.; Hughes, S.H.; Arnold, E. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 10027-10032.
89. Gotte, M. Mechanisms of resistance associated with excision of incorporated nucleotide analogue inhibitors of HIV-1 reverse transcriptase. Curr. Opin. HIV AIDS 2007, 2, 103-107.
90. Theys, K.; Deforche, K.; Libin, P.; Camacho, R.J.; Van Laethem, K.; Vandamme, A.M. Resistance pathways of human immunodeficiency virus type 1 against the combination of zidovudine and lamivudine. J. Gen. Virol. 2010, 91, 1898-1908.
91. Quan, Y.; Brenner, B.G.; Oliveira, M.; Wainberg, M.A. Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation. Antimicrob. Agents Chemother. 2003, 47, 747-754.
92. Menendez-Arias, L. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. Virus Res. 2008, 134, 124-146.
93. Menendez-Arias, L.; Matamoros, T.; Cases-Gonzalez, C.E. Insertions and deletions in HIV-1 reverse transcriptase: consequences for drug resistance and viral fitness. Curr. Pharm. Des. 2006, 12, 1811-1825.
94. Miller, M.D.; Margot, N.A.; Hertogs, K.; Larder, B.; Miller, V. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleos. Nucleot. Nucleic Acids 2001, 20, 1025-1028.
95. Nikolenko, G.N.; Delviks-Frankenberry, K.A.; Palmer, S.; Maldarelli, F.; Fivash, M.J. Jr.; Coffin, J.M.; Pathak, V.K. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 317-322.
96. Brehm, J.H.; Koontz, D.; Meteer, J.D.; Pathak, V.; Sluis-Cremer, N.; Mellors, J.W. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine. J. Virol. 2007, 81, 7852-7859.
97. Delviks-Frankenberry, K.A.; Nikolenko, G.N.; Barr, R.; Pathak, V.K. Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance. J. Virol. 2007, 81, 6837-6845.
98. Ren, J.; Stammers, D.K. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. Virus Res. 2008, 134, 157-170.
99. Ding, J.; Das, K.; Hsiou, Y.; Sarafianos, S.G.; Clark, A.D., Jr.; Jacobo-Molina, A.; Tantillo, C.; Hughes, S.H.; Arnold, E. Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution. J. Mol. Biol. 1998, 284, 1095-1111.
100. Bernstein, H.J. Recent changes to RasMol, recombining the variants. Trends Biochem. Sci. 2000, 25, 453-455.
101. Sayle, R.A.; Milner-White, E.J. RASMOL: Biomolecular graphics for all. Trends Biochem. Sci. 1995, 20, 374.
102. Delgado, J.; Shulman, N. NNRTI hypersusceptibility. AIDS Read. 2005, 15, 28-30, 32-24.
103. Haubrich, R.H.; Jiang, H.; Swanstrom, R.; Bates, M.; Katzenstein, D.; Petch, L.; Fletcher, C.V.; Fiscus, S.A.; Gulick, R.M. Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359. HIV Clin. Trials 2007, 8, 63-67.
104. Shulman, N.S.; Delgado, J.; Bosch, R.J.; Winters, M.A.; Johnston, E.; Shafer, R.W.; Katzenstein, D.A.; Merigan, T.C. Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assays. J. Acquir. Immune Defic. Syndr. 2005, 39, 78-81.
105. Ambrose, Z.; Herman, B.D.; Sheen, C.W.; Zelina, S.; Moore, K.L.; Tachedjian, G.; Nissley, D.V.; Sluis-Cremer, N. The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs. J. Virol. 2009, 83, 3826-3833.
106. Clark, S.A.; Shulman, N.S.; Bosch, R.J.; Mellors, J.W. Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors. AIDS 2006, 20, 981-984.
107. Demeter, L.M.; DeGruttola, V.; Lustgarten, S.; Bettendorf, D.; Fischl, M.; Eshleman, S.; Spreen, W.; Nguyen, B.Y.; Koval, C.E.; Eron, J.J.; Hammer, S.; Squires, K. Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. HIV Clin. Trials 2008, 9, 11-25.
108. Anderson, J.; Schiffer, C.; Lee, S.K.; Swanstrom, R. Viral protease inhibitors. Handb. Exp. Pharmacol. 2009, 85-110.
109. Lefebvre, E.; Schiffer, C.A. Resilience to resistance of HIV-1 protease inhibitors: Profile of darunavir. AIDS Rev. 2008, 10, 131-142.
110. Nalam, M.N.; Schiffer, C.A. New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors. Curr. Opin. HIV AIDS 2008, 3, 642-646.
111. Shafer, R.W.; Schapiro, J.M. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev. 2008, 10, 67-84.
112. Turner, D.; Schapiro, J.M.; Brenner, B.G.; Wainberg, M.A. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients. Antivir. Ther. 2004, 9, 301-314.
113. Mathias, A.A.; German, P.; Murray, B.P.; Wei, L.; Jain, A.; West, S.; Warren, D.; Hui, J.; Kearney, B.P. Pharmacokinetics and pharmacodynamics of GS-9350: A novel pharmacokinetic enhancer without anti-HIV activity. Clin. Pharmacol. Ther. 2010, 87, 322-329.
114. Prabu-Jeyabalan, M.; Nalivaika, E.; Schiffer, C.A. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 2002, 10, 369-381.
115. Whitcomb, J.M.; Huang, W.; Fransen, S.; Limoli, K.; Toma, J.; Wrin, T.; Chappey, C.; Kiss, L.D.; Paxinos, E.E.; Petropoulos, C.J. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob. Agents Chemother. 2007, 51, 566-575.
116. Lalezari, J.P.; Henry, K.; O'Hearn, M.; Montaner, J.S.; Piliero, P.J.; Trottier, B.; Walmsley, S.; Cohen, C.; Kuritzkes, D.R.; Eron, J.J., Jr.; Chung, J.; DeMasi, R.; Donatacci, L.; Drobnes, C.; Delehanty, J.; Salgo, M. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 2003, 348, 2175-2185.
117. Lazzarin, A.; Clotet, B.; Cooper, D.; Reynes, J.; Arasteh, K.; Nelson, M.; Katlama, C.; Stellbrink, H.J.; Delfraissy, J.F.; Lange, J.; Huson, L.; DeMasi, R.; Wat, C.; Delehanty, J.; Drobnes, C.; Salgo, M. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 2003, 348, 2186-2195.
118. Melby, T.; Sista, P.; DeMasi, R.; Kirkland, T.; Roberts, N.; Salgo, M.; Heilek-Snyder, G.; Cammack, N.; Matthews, T.J.; Greenberg, M.L. Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res. Hum. Retroviruses 2006, 22, 375-385.
119. Poveda, E.; Rodes, B.; Labernardiere, J.L.; Benito, J.M.; Toro, C.; Gonzalez-Lahoz, J.; Faudon, J.L.; Clavel, F.; Schapiro, J.; Soriano, V. Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J. Med. Virol. 2004, 74, 21-28.
120. Deeks, S.G.; Lu, J.; Hoh, R.; Neilands, T.B.; Beatty, G.; Huang, W.; Liegler, T.; Hunt, P.; Martin, J.N.; Kuritzkes, D.R. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J. Infect. Dis. 2007, 195, 387-391.
121. Hazuda, D.J.; Young, S.D.; Guare, J.P.; Anthony, N.J.; Gomez, R.P.; Wai, J.S.; Vacca, J.P.; Handt, L.; Motzel, S.L.; Klein, H.J.; et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004, 305, 528-532.
122. Steigbigel, R.T.; Cooper, D.A.; Kumar, P.N.; Eron, J.E.; Schechter, M.; Markowitz, M.; Loutfy, M.R.; Lennox, J.L.; Gatell, J.M.; Rockstroh, J.K.; et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 2008, 359, 339-354.
123. Zahm, J.A.; Bera, S.; Pandey, K.K.; Vora, A.; Stillmock, K.; Hazuda, D.; Grandgenett, D.P. Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistance. Antimicrob. Agents Chemother. 2008, 52, 3358-3368.
124. Grant, P.; Zolopa, A. Integrase inhibitors: A clinical review of raltegravir and elvitegravir. J. HIV Ther. 2008, 13, 36-39.
125. Hatano, H.; Lampiris, H.; Fransen, S.; Gupta, S.; Huang, W.; Hoh, R.; Martin, J.N.; Lalezari, J.; Bangsberg, D.; Petropoulos, C.; Deeks, S.G. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 2010, 54, 389-393.
126. Schafer, J.J.; Squires, K.E. Integrase inhibitors: A novel class of antiretroviral agents. Ann. Pharmacother. 2010, 44, 145-156.
127. Clotet, B.; C.K.; Lalezari, J.; Young, B.; Huang, J.; Underwood, M.R.; Ait-Khaled, M.; Nichols, W.G. HIV integrase resistance profiles and S/GSK1349572 baseline phenotypic susceptibility for individuals experiencing virological failure on raltegravir and enrolling in the VIKING phase IIb Pilot study (ING112961). Antivir. Ther. 2010, 15, A:61.
128. Hare, S.; Gupta, S.S.; Valkov, E.; Engelman, A.; Cherepanov, P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010, 464, 232-236.
129. Brenner, B.G. Resistance and viral subtypes: How important are the differences and why do they occur? Curr. Opin. HIV AIDS 2007, 2, 94-102.
130. Martinez-Cajas, J.L.; Pant-Pai, N.; Klein, M.B.; Wainberg, M.A. Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: A systematic review of virologic and biochemical evidence. AIDS Rev. 2008, 10, 212-223.
131. Bandaranayake, R.M.; Kolli, M.; King, N.M.; Nalivaika, E.; Heroux, A.; Kakizawa, J.; Sugiura, W.; Schiffer, C.A. The Effect of Clade Specific Sequence Polymorphisms on HIV-1 Protease Activity and Inhibitor Resistance Pathways. J. Virol. 2010, 84, 9995-10003.
132. Brenner, B.; Turner, D.; Oliveira, M.; Moisi, D.; Detorio, M.; Carobene, M.; Marlink, R.G.; Schapiro, J.; Roger, M.; Wainberg, M.A. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003, 17, F1-F5.
133. Loemba, H.; Brenner, B.; Parniak, M.A.; Ma'ayan, S.; Spira, B.; Moisi, D.; Oliveira, M.; Detorio, M.; Wainberg, M.A. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob. Agents Chemother. 2002, 46, 2087-2094.
134. Champenois, K.; Bocket, L.; Deuffic-Burban, S.; Cotte, L.; Andre, P.; Choisy, P.; Yazdanpanah, Y. Expected response to protease inhibitors of HIV-1 non-B subtype viruses according to resistance algorithms. AIDS 2008, 22, 1087-1089.
135. D'Arrigo, R.; Ciccozzi, M.; Gori, C.; Montieri, S.; Aquaro, S.; Bellagamba, R.; Boumis, E.; Di Perri, G.; Pizzi, D.; Antinori, A.; Rezza, G.; Perno, C.F. gp41 sequence variability in HIV type 1 non-B subtypes infected patients undergoing enfuvirtide pressure. AIDS Res. Hum. Retroviruses 2007, 23, 1296-1302.
136. Geretti, A.M.; Harrison, L.; Green, H.; Sabin, C.; Hill, T.; Fearnhill, E.; Pillay, D.; Dunn, D. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin. Infect. Dis. 2009, 48, 1296-1305.
137. Holguin, A.; Faudon, J.L.; Labernardiere, J.L.; Soriano, V. Susceptibility of HIV-1 non-B subtypes and recombinant variants to Enfuvirtide. J. Clin. Virol. 2007, 38, 176-180.
138. Martinez-Cajas, J.L.; Pai, N.P.; Klein, M.B.; Wainberg, M.A. Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008). J. Int. AIDS Soc. 2009, 12, 11.
139. Maiga, A.I.; Descamps, D.; Morand-Joubert, L.; Malet, I.; Derache, A.; Cisse, M.; Koita, V.; Akonde, A.; Diarra, B.; Wirden, M.; et al. Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naive patients infected with non-B HIV-1 subtypes. Antimicrob. Agents Chemother. 2010, 54, 728-733.
140. Garrido, C.; Geretti, A.M.; Zahonero, N.; Booth, C.; Strang, A.; Soriano, V.; De Mendoza, C. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. J. Antimicrob. Chemother. 2010, 65, 320-326.
141. Gottlieb, G.S.; Badiane, N.M.; Hawes, S.E.; Fortes, L.; Toure, M.; Ndour, C.T.; Starling, A.K.; Traore, F.; Sall, F.; Wong, K.G.; et al. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: Implications for HIV-2 treatment in resouce-limited West Africa. Clin. Infect. Dis. 2009, 48, 476-483.
142. Ntemgwa, M.L.; d'Aquin Toni, T.; Brenner, B.G.; Camacho, R.J.; Wainberg, M.A. Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob. Agents Chemother. 2009, 53, 3611-3619.
143. Nettles, R.E.; Kieffer, T.L.; Kwon, P.; Monie, D.; Han, Y.; Parsons, T.; Cofrancesco, J. Jr.; Gallant, J.E.; Quinn, T.C.; Jackson, B.; Flexner, C.; Carson, K.; Ray, S.; Persaud, D.; Siliciano, R.F. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005, 293, 817-829.
144. Lima, V.; Harrigan, R.; Montaner, J.S. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay. J. Acquir. Immune Defic. Syndr. 2009, 51, 3-6.
145. Smit, E.; Bhattacharya, S.; Osman, H.; Taylor, S. Increased frequency of HIV-1 viral load blip rate observed after switching from Roche Cobas Amplicor to Cobas Taqman assay. J. Acquir. Immune Defic. Syndr. 2009, 51, 364-365.
146. Yao, J.D.; Germer, J.J.; Damond, F.; Roquebert, B.; Descamps, D. Plasma load discrepancies between the Roche Cobas Amplicor human immunodeficiency virus type 1 (HIV-1) Monitor version 1.5 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 assays. J. Clin. Microbiol. 2008, 46, 834; author reply 834.
147. Manavi, K. The significance of low-level plasma HIV viral load on COBAS TaqMan HIV-1 assays for patients with undetectable plasma viral load on COBAS Amplicor monitor version 1.5. HIV Clin. Trials 2008, 9, 283-286.
148. Parikh, U.M.; Zelina, S.; Sluis-Cremer, N.; Mellors, J.W. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. AIDS 2007, 21, 1405-1414.
149. AIDSINFO. Available online: http://www.aidsinfo.nih.gov/ (accessed on 21 February 2011).
150. Dykes, C.; Najjar, J.; Bosch, R.J.; Wantman, M.; Furtado, M.; Hart, S.; Hammer, S.M.; Demeter, L.M. Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine. J. Infect. Dis. 2004, 189, 1091-1096.
151. Johnson, J.A.; Li, J.F.; Wei, X.; Lipscomb, J.; Bennett, D.; Brant, A.; Cong, M.E.; Spira, T.; Shafer, R.W.; Heneine, W. Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations. PLoS ONE 2007, 2, e638.
152. Palmer, S.; Boltz, V.; Martinson, N.; Maldarelli, F.; Gray, G.; McIntyre, J.; Mellors, J.; Morris, L.; Coffin, J. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 7094-7099.
153. Palmer, S.; Kearney, M.; Maldarelli, F.; Halvas, E.K.; Bixby, C.J.; Bazmi, H.; Rock, D.; Falloon, J.; Davey, R.T. Jr.; Dewar, R.L.; Metcalf, J.A.; Hammer, S.; Mellors, J.W.; Coffin, J.M. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J. Clin. Microbiol. 2005, 43, 406-413.
154. Coffin, J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267, 483-489.
155. Johnson, J.A.; Geretti, A.M. Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution. J. Antimicrob. Chemother. 2010, 65, 1322-1326.
156. Geretti, A.M.; Fox, Z.V.; Booth, C.L.; Smith, C.J.; Phillips, A.N.; Johnson, M.; Li, J.F.; Heneine, W.; Johnson, J.A. Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 2009, 52, 569-573.
157. Johnson, J.A.; Li, J.F.; Wei, X.; Lipscomb, J.; Irlbeck, D.; Craig, C.; Smith, A.; Bennett, D.E.; Monsour, M.; Sandstrom, P.; Lanier, E.R.; Heneine, W. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med. 2008, 5, e158.
158. Paredes, R.; Lalama, C.M.; Ribaudo, H.J.; Schackman, B.R.; Shikuma, C.; Giguel, F.; Meyer, W.A., 3rd; Johnson, V.A.; Fiscus, S.A.; D'Aquila, R.T.; Gulick, R.M.; Kuritzkes, D.R. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J. Infect. Dis. 2010, 201, 662-671.
159. Arribas, J.R.; Horban, A.; Gerstoft, J.; Fatkenheuer, G.; Nelson, M.; Clumeck, N.; Pulido, F.; Hill, A.; van Delft, Y.; Stark, T.; Moecklinghoff, C. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/mL. AIDS 2010, 24, 223-230.
160. Boltz, V.; Lockman, Y.Z. S; Hong, F.; Halvas, E.; McIntyre, J.; Currier, J.; Hughes, M.; Coffin, J.; Mellors, J.; A5208 OCTANE Study Team. NNRTI-resistant Variants Detected by Allele-specific PCR Predict Outcome of NVP-containing ART in Women with Prior Exposure to sdNVP: Results from the OCTANE/A5208 Study. In Proceedings of the Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA, 16-19 February 2010.
161. Hedskog, C.; Mild, M.; Jernberg, J.; Sherwood, E.; Bratt, G.; Leitner, T.; Lundeberg, J.; Andersson, B.; Albert, J. Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing. PLoS ONE 2010, 5, e11345.
162. Lataillade, M.; Chiarella, J.; Yang, R.; Schnittman, S.; Wirtz, V.; Uy, J.; Seekins, D.; Krystal, M.; Mancini, M.; McGrath, D.; Simen, B.; Egholm, M.; Kozal, M. Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study. PLoS ONE 2010, 5, e10952.
163. Le, T.; Chiarella, J.; Simen, B.B.; Hanczaruk, B.; Egholm, M.; Landry, M.L.; Dieckhaus, K.; Rosen, M.I.; Kozal, M.J. Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLoS ONE 2009, 4, e6079.
164. Mitsuya, Y.; Varghese, V.; Wang, C.; Liu, T.F.; Holmes, S.P.; Jayakumar, P.; Gharizadeh, B.; Ronaghi, M.; Klein, D.; Fessel, W.J.; Shafer, R.W. Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations. J. Virol. 2008, 82, 10747-10755.
165. Archer, J.; Braverman, M.S.; Taillon, B.E.; Desany, B.; James, I.; Harrigan, P.R.; Lewis, M.; Robertson, D.L. Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS 2009, 23, 1209-1218.
166. Martinez-Picado, J.; Martinez, M.A. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: A view from the clinic and ex vivo. Virus Res 2008, 134, 104-123.
167. Hu, Z.; Giguel, F.; Hatano, H.; Reid, P.; Lu, J.; Kuritzkes, D.R. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J. Virol. 2006, 80, 7020-7027.
168. Hu, Z.; Hatano, H.; Hammond, S.P.; Smith, D.; Wild, M.; Gupta, S.; Whitcomb, J.; Kalayjian, R.C.; Gripshover, B.; Kuritzkes, D.R. Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase. J. Acquir. Immune Defic. Syndr. 2007, 45, 494-500.
169. Hu, Z.; Kuritzkes, D.R. Effect of Raltegravir Resistance Mutations in HIV-1 Integrase on Viral Fitness. J. Acquir. Immune Defic. Syndr. 2010, 55, 148-155.
170. Lu, J.; Sista, P.; Giguel, F.; Greenberg, M.; Kuritzkes, D.R. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J. Virol. 2004, 78, 4628-4637.
171. Paredes, R.; Sagar, M.; Marconi, V.C.; Hoh, R.; Martin, J.N.; Parkin, N.T.; Petropoulos, C.J.; Deeks, S.G.; Kuritzkes, D.R. In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J. Virol. 2009, 83, 2038-2043.
172. Barbour, J.D.; Hecht, F.M.; Wrin, T.; Segal, M.R.; Ramstead, C.A.; Liegler, T.J.; Busch, M.P.; Petropoulos, C.J.; Hellmann, N.S.; Kahn, J.O.; Grant, R.M. Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection. J. Infect. Dis. 2004, 190, 251-256.
173. Fransen, S.; Karmochkine, M.; Huang, W.; Weiss, L.; Petropoulos, C.J.; Charpentier, C. Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure. Antimicrob. Agents Chemother. 2009, 53, 4522-4524.
174. Picchio, G.R.; Valdez, H.; Sabbe, R.; Landay, A.L.; Kuritzkes, D.R.; Lederman, M.M.; Mosier, D.E. Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy. J. Acquir. Immune Defic. Syndr. 2000, 25, 289-295.
175. Huang, Y.; Wu, H.; Acosta, E.P. Hierarchical Bayesian inference for HIV dynamic differential equation models incorporating multiple treatment factors. Biom J. 2010, 52, 470-486.
176. Prosperi, M.C.; Altmann, A.; Rosen-Zvi, M.; Aharoni, E.; Borgulya, G.; Bazso, F.; Sonnerborg, A.; Schulter, E.; Struck, D.; Ulivi, G.; Vandamme, A.M.; Vercauteren, J.; Zazzi, M. Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment. Antivir. Ther. 2009, 14, 433-442.
177. Revell, A.D.; Wang, D.; Harrigan, R.; Hamers, R.L.; Wensing, A.M.; Dewolf, F.; Nelson, M.; Geretti, A.M.; Larder, B.A. Modelling response to HIV therapy without a genotype: an argument for viral load monitoring in resource-limited settings. J. Antimicrob. Chemother. 2010, 65, 605-607.
178. Swindells, S.; DiRienzo, A.G.; Wilkin, T.; Fletcher, C.V.; Margolis, D.M.; Thal, G.D.; Godfrey, C.; Bastow, B.; Ray, M.G.; Wang, H.; Coombs, R.W.; McKinnon, J.; Mellors, J.W. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 2006, 296, 806-814.
179. Wilkin, T.J.; McKinnon, J.E.; DiRienzo, A.G.; Mollan, K.; Fletcher, C.V.; Margolis, D.M.; Bastow, B.; Thal, G.; Woodward, W.; Godfrey, C.; et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J. Infect. Dis. 2009, 199, 866-871.